Patent ID: 6420393
Filing Date: 2002-07-16
Classification: A61P,C07D

Abstract:
A method of treating a nuclear factor &kgr;B-dependent disease selected from the group consisting of inflammatory diseases, immunological disorders, septic shock, transplant rejection, radiation damage, reperfusion injuries after ischemia, stroke or cerebral trauma, cirrhosis of the liver, asthma, arteriosclerosis and multiple sclerosis, comprising administering to a mammal in need thereof a therapeutically effective amount of a nuclear factor &kgr;B inhibiting cyclopentabenzofuran compound of the formula (I) in whichR1 and R3 independently of one another in each case represent hydrogen, halogen or alkyl, R2 and R4 independently of one another in each case represent halogen, alkyl or optionally substituted alkoxy, R5 represents hydroxyl, alkylamino or the radical â€”NR12â€”CHR13â€”COOR14, in which R12 represents hydrogen or alkyl, R13 represents one of the radicals of a natural &agr;-amino acid, where functional groups can optionally be present in protected form, or R12 and R13 together represent â€”(CH2)3â€” and â€”(CH2)4â€”, and R14 represents alkyl, benzyl or another C-terminal protective group, R6 represents hydrogen or R5 and R6 together represent oxygen (oxo), R7 and R8 in each case represent hydrogen, R9 represents optionally substituted phenyl or hetaryl, R10 represents hydrogen, halogen, alkyl or alkoxy and R11 represents hydrogen, halogen or alkyl, or a pharmaceutically acceptable salt thereof.